Autologous protein solution inhibits MMP-13 production by IL-1beta and TNF alpha-stimulated human articular chondrocytes

Author: Woodell-May et al
Year: 2011

Abstract

Catabolic inflammatory cytokines are prevalent in osteoarthritis (OA). The purpose of this study was to evaluate an auto-logous protein solution (APS) as a potential chondroprotective agent for OA therapy. APS was prepared from platelet-rich plasma (PRP). The APS solution contained both anabolic (bFGF, TGF-b1, TGF-b2, EGF, IGF-1, PDGF-AB, PDGF-BB, and VEGF) and anti- inflammatory (IL-1ra, sTNF-RI, sTNF-RII, IL-4, IL-10, IL-13, and IFNg) cytokines but low concentrations of catabolic cytokines (IL-1a, IL-1b, TNFa, IL-6, IL-8, IL-17, and IL-18). Human articular chondrocytes were pre-incubated with the antagonists IL-1ra, sTNF-RI, or APS prior to the addition of recombinant human IL-1b or TNFa. Following exposure to inflammatory cytokines, the levels of MMP-13 in the culture medium were evaluated by ELISA. MMP-13 production stimulated in chondrocytes by IL-1b or TNFa was reduced by rhIL-1ra and sTNF-RI to near basal levels. APS was also capable of inhibiting the production of MMP-13 induced by both IL-1b and TNFa. The combination of anabolic and anti-inflammatory cytokines in the APS created from PRP may render this formulation to be a potential candidate for the treatment of inflammation in patients at early stages of OA.

https://www.ncbi.nlm.nih.gov/pubmed/21437966

Get in touch

Find your clinic

We offer appointments nationwide and now working with partners abroad providing cutting edge Regenerative Medicine to patients in UK, Italy, Australia, Spain and Pakistan.